Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuroleptic malignant syndrome

J Kornhuber1, M Weller

  • 1Department of Psychiatry, University of Würzburg, Germany.

Current Opinion in Neurology
|August 1, 1994
PubMed
Summary
This summary is machine-generated.

Neuroleptic malignant syndrome (NMS) is a severe reaction to certain medications, marked by muscle rigidity and fever. Early recognition and drug withdrawal are key to good outcomes in NMS management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sphingolipids in Emotional Well-Being.

Journal of neurochemistry·2026
Same author

Association between benzodiazepine receptor agonist use and mortality in patients hospitalised for COVID-19: a multicentre observational study.

Epidemiology and psychiatric sciences·2022
Same author

Individual differences in inflammatory and oxidative mechanisms of stress-related mood disorders.

Frontiers in neuroendocrinology·2019
Same author

Correlation of CSF- and MRI-Biomarkers and Progression of Cognitive Decline in an Open Label MCI Trial.

The journal of prevention of Alzheimer's disease·2018
Same author

Epigenetic control of epilepsy target genes contributes to a cellular memory of epileptogenesis in cultured rat hippocampal neurons.

Acta neuropathologica communications·2017
Same author

Prenatal and adult androgen activities in alcohol dependence.

Acta psychiatrica Scandinavica·2017
Same journal

Movement disorders and Parkinson's disease: collaborative and interdisciplinary research to advance understanding of neural circuit dysfunction, pathophysiology, and care: new horizons in technology, neuroimaging, neurophysiology, and genetics toward personalized medicine.

Current opinion in neurology·2026
Same journal

Editorial introduction.

Current opinion in neurology·2026
Same journal

Multimodal mapping of balance dysfunction in Parkinson's disease: a consensus roadmap for research and intervention.

Current opinion in neurology·2026
Same journal

Tourette syndrome: brain neurophysiology, circuit dysfunction, and neuromodulation across invasive and noninvasive approaches.

Current opinion in neurology·2026
Same journal

Dystonia: from phenotypes to genetics and therapeutic advances.

Current opinion in neurology·2026
Same journal

What can we learn from eye movements in movement disorders and Parkinson's disease?

Current opinion in neurology·2026
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology
  • Neurology

Background:

  • Neuroleptic malignant syndrome (NMS) is a critical condition linked to dopamine receptor antagonists.
  • NMS presents with extrapyramidal symptoms, hyperthermia, and elevated creatine kinase.
  • Evolving understanding includes non-neuroleptic drugs and Parkinson's disease medication withdrawal as triggers.

Purpose of the Study:

  • To review the evolving concepts and management of Neuroleptic Malignant Syndrome (NMS).
  • To highlight the neurochemical underpinnings and therapeutic strategies for NMS.

Main Methods:

  • Review of clinical recognition and diagnostic criteria for NMS.
  • Analysis of neurochemical mechanisms involving dopamine deficiency and excitatory amino acid neurotransmission.

Related Experiment Videos

  • Evaluation of management strategies, including supportive care and controversial treatments.

    • Main Results:

    • Functional dopamine deficiency is a probable neurochemical feature in NMS and related conditions.
    • Prompt discontinuation of causative agents or readjustment of Parkinson's therapy improves outcomes.
    • Supportive care for hyperthermia and fluid balance is crucial.

    Conclusions:

    • Early recognition of NMS is paramount for effective management.
    • While re-exposure risk exists, atypical neuroleptics like clozapine may be safer for psychiatric patients with NMS history.
    • Further research into excitatory amino acid antagonists and dopamine agonists for NMS treatment is ongoing.